Healthcare
The changes are unlikely to help people in developing countries but could reduce innovation among biopharma companies and ultimately do more harm than good.
Genentech’s flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
On Thursday at the White House, President Biden paid tribute to the 1 million American lives lost due to COVID-19.
bit.bio announced Monday that it has launched its Huntington’s Disease (HD) cell model to accelerate drug discovery and screening for patients with the disease.
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
AstraZeneca and Daiichi Sankyo’s breast cancer therapeutic Enhertu received supplemental approval for an earlier form of breast cancer from the U.S. Food and Drug Administration.
New research indicates the heart that David Bennet received was infected with porcine cytomegalovirus, a virus that can cause respiratory and pregnancy complications in pigs.
The FDA has approved two of Phathom Pharmaceuticals’ products for bacterial illnesses in adults: Voquezna Triple Pak and Voquezna Dual Pak.
Novartis’ Kisqali (ribociclib) plus the chemotherapy drug fulvestrant provided some post-menopausal breast cancer patients’ survival benefit of more than five-and-a-half years of life.
The WHO issued an alarming statement that details a 79% increase in child measles outbreaks globally, as well as a warning that 11 countries have reported peculiar acute cases of hepatitis in children.
PRESS RELEASES